EAU guidelines on testicular cancer: 2011 update

European Urology

Volumn 60, Issue 2, 2011, Pages 304-319

  Albers, Peter ^a   Albrecht, Walter ^b   Algaba, Ferran ^c   Bokemeyer, Carsten ^d   Cohn Cedermark, Gabriella ^e   Fizazi, Karim ^f   Horwich, Alan ^g   Laguna, Maria Pilar ^h  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Rudolfstiftung   (Austria)

^c FUNDACIÓ PUIGVERT   (Spain)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Assessment; Diagnosis; EAU Guidelines; Follow up; Testicular cancer; Treatment

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; TUMOR MARKER; VINBLASTINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTINUOUS INFUSION; FOLLOW UP; GERM CELL TUMOR; HEALTH CARE ORGANIZATION; HUMAN; LYMPH NODE DISSECTION; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEMINOMA; SYSTEMATIC REVIEW; TESTIS CANCER; TREATMENT PLANNING; TUMOR CLASSIFICATION;

ADULT; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SOCIETIES, MEDICAL; TESTICULAR NEOPLASMS; UROLOGY;

EID: 79959546636     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.038     Document Type: Article

References (98)

1. C. La Vecchia, C. Bosetti, and F. Lucchini Cancer mortality in Europe, 2000-2004, and an overview of trends since 1995 Ann Oncol 21 2010 1323 1360
2. Curado MP, Edwards B, Shin R, et al, editors. Cancer incidence in five continents, vol 9. IARC Scientific Publications No. 160. Lyon, France: International Association for Research on Cancer; 2007.
3. G. Engholm, J. Ferlay, and N. Christensen NORDCAN - a Nordic tool for cancer information, planning, quality control and research Acta Oncol 49 2010 725 736
4. WHO histological classification of testis tumours. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and genetics. Tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004. p. 250-62.
5. A. Jones, J.N. Fergus, and J. Chapman Is surveillance for stage I germ cell tumours of the testis appropriate outside a specialist centre? BJU Int 84 1999 79 84 (Pubitemid 29346779)
6. L. Collette, R.J. Sylvester, and S.P. Stenning Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party J Natl Cancer Inst 91 1999 839 846
7. U. Capitanio, C. Jeldres, and P. Perrotte Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors Urology 74 2009 373 377
8. A. Fléchon, E. Tavernier, and H. Boyle Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour BJU Int 106 2010 779 785
9. M.D. Shelley, K. Burgon, and M.D. Mason Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review Cancer Treat Rev 28 2002 237 253 (Pubitemid 35439438)
10. S. Krege, J. Beyer, and R. Souchon European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I Eur Urol 53 2008 478 496
11. S. Krege, J. Beyer, and R. Souchon European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II Eur Urol 53 2008 497 513
12. Oxford Centre for Evidence-Based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick, March 2009. Centre for Evidence Based Medicine Web site. http://www.cebm.net/index.aspx?o=5653. Accessed April 2011.
13. K.P. Dieckmann, J.T. Hartmann, and J. Classen Is increased body mass index associated with the incidence of testicular germ cell cancer? J Cancer Res Clin Oncol 135 2009 731 738
14. H. Møller, A. Prener, and N.E. Skakkebaek Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark Cancer Causes Control 7 1996 264 274 (Pubitemid 26156671)
15. J. Shaw Diagnosis and treatment of testicular cancer Am Fam Physician 77 2008 469 474
16. J.C. Angulo, J. Gonzalez, and N. Rodriguez Clinicopathological study of regressed testicular tumors (apparent extragonadal germ cell neoplasms) J Urol 182 2009 2303 2310
17. M. Mancini, L. Carmignani, and G. Gazzano High prevalence of testicular cancer in azoospermic men without spermatogenesis Hum Reprod 22 2007 1042 1046
18. J.R. Germ-Lluch, X. Garcia del Muro, and P. Maroto On behalf of the Spanish Germ-Cell Cancer Group (GG). Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG) Eur Urol 42 2002 553 563 (Pubitemid 35462333)
19. E.A. Klein Tumour markers in testis cancer Urol Clin North Am 20 1993 67 73
20. Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. In: UICC International Union Against Cancer, ed. 7. New York, NY: Wiley-Blackwell; 2009. p. 249-54.
21. J. Tabernero, L. Paz-Ares, and R. Salazar Incidence of contralateral germ cell testicular tumours in South Europe: report of the experience at 2 Spanish university hospitals and review of the literature J Urol 171 2004 164 167 (Pubitemid 37549115)
22. H.W. Herr, and J. Sheinfeld Is biopsy of the contralateral testis necessary in patients with germ cell tumors? J Urol 158 1997 1331 1334 (Pubitemid 27391190)
23. K.-P. Dieckmann, M. Kulejewski, U. Pichlmeier, and V. Loy Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy Eur Urol 51 2007 175 185 discussion 183-5 (Pubitemid 44821512)
24. A. Heidenreich, L. Weissbach, and W. Holth Organ sparing surgery for malignant germ cell tumour of the testis J Urol 166 2001 2161 2165 (Pubitemid 33065246)
25. R. Souchon, U. Gertenbach, and K.P. Dieckmann Contralateral testicular cancer in spite of TIN-negative double biopsies and interval cisplatin chemotherapy J Strahlenther Onkol 182 2006 289 292
26. International Germ Cell Cancer Collaborative Group International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers J Clin Oncol 15 1997 594 603
27. W.A. See, and L. Hoxie Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results J Urol 150 1993 874 878 (Pubitemid 23241288)
28. M. de Wit, W. Brenner, and M. Hartmann [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial Ann Oncol 19 2008 1619 1623
29. M. De Santis, A. Becherer, and C. Bokemeyer 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial J Clin Oncol 22 2004 1034 1039 (Pubitemid 41095035)
30. K. Oechsle, M. Hartmann, and W. Brenner [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group J Clin Oncol 26 2008 5930 5935
31. O. Klepp, P. Flodgren, and H. Maartman-Moe Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre and postorchidectomy serum tumour marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA) Ann Oncol 1 1990 281 288 (Pubitemid 20377098)
32. D. Schottenfeld, M.E. Warshauer, and S. Sherlock The epidemiology of testicular cancer in young adults Am J Epidemiol 112 1980 232 246 (Pubitemid 10018961)
33. C.N. Sternberg The management of stage I testis cancer Urol Clin North Am 25 1998 435 449 (Pubitemid 28384608)
34. T. Tandstad, R. Smaaland, and A. Solberg Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group (SWENOTECA) J Clin Oncol 29 2011 719 725
35. J. Aparicio, X. García del Muro, and P. Maroto Multicenter study evaluating a dual policy of postorchidectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma Ann Oncol 14 2003 867 872 (Pubitemid 36827202)
36. P. Chung, C. Parker, and T. Panzarella Surveillance in stage I testicular seminoma-risk of late relapse Can J Urol 9 2002 1637 1640
37. S.D. Foss, A. Horwich, and J.M. Russell Optimal planning target volume for stage I testicular seminoma: A Medical Research Council Testicular Tumor Working Group randomized trial J Clin Oncol 17 1999 1146
38. W.G. Jones, S.D. Fossa, and G.M. Mead A randomized trial of two radiotherapy schedules in the adjuvant treatment of stage I seminoma (MRC TE 18) Eur J Cancer 37 Suppl 6 2001 S157 Abstract 572
39. R.T. Oliver, G.M. Mead, and G.J. Rustin Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214) J Clin Oncol 29 2011 957 962
40. P. Schoffski, N. Höhn, and R. Kowalski Health-related quality of life (QoL) in patients with seminoma stage I treated with either adjuvant radiotherapy (RT) or two cycles of carboplatinum chemotherapy (CT): results of a randomized phase III trial of the German Interdisciplinary Working Party on Testicular Cancer. ASCO Annual Meeting Proceedings. Part 1 J Clin Oncol 25 Suppl 18S 2007 5050
41. J. Aparicio, J.R. Germ, and X. García del Muro Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study J Clin Oncol 23 2005 8717 8723 (Pubitemid 46211516)
42. D. Robinson, H. Møller, and A. Horwich Mortality and incidence of second cancers following treatment for testicular cancer Br J Cancer 96 2007 529 533 (Pubitemid 46215229)
43. S. Bieri, M. Rouzaud, and R. Miralbell Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 50 1999 349 353 (Pubitemid 29207538)
44. A.W. van den Belt-Dusebout, R. de Wit, and J.A. Gietema Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer J Clin Oncol 25 2007 4370 4378 (Pubitemid 350013842)
45. N. Warszawski, and M. Schmucking Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy Scan J Urol Nephrol 31 1997 335 339
46. R.T. Oliver, J. Ong, and J. Shamash Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with stage 1 nonseminoma treated with adjuvant chemotherapy Urology 63 2004 556 561
47. A. Zuniga, D. Kakiashvili, and M.A. Jewett Surveillance in stage I nonseminomatous germ cell tumours of the testis BJU Int 104 2009 1351 1356
48. C. Kollmannsberger, C. Moore, and K.N. Chi Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy Ann Oncol 21 2010 1296 1301
49. M.H. Cullen, S.P. Stenning, and M.C. Parkinson Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report J Clin Oncol 14 1996 1106 1113 (Pubitemid 26105516)
50. U.E. Studer, M.F. Fey, and A. Calderoni Adjuvant chemotherapy after orchidectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer Eur Urol 23 1993 444 449 (Pubitemid 23187349)
51. C. Chevreau, C. Mazerolles, and M. Soulié Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion Eur Urol 46 2004 209 215
52. R.A. Huddart, A. Norman, and M. Shahidi Cardiovascular disease as a long-term complication of treatment for testicular cancer J Clin Oncol 21 2003 1513 1523 (Pubitemid 46594104)
53. J. Baniel, R.S. Foster, and R. Gonin Late relapse of testicular cancer J Clin Oncol 13 1995 1170 1176
54. G.J. Rustin, G.M. Mead, and S.P. Stenning Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197-the National Cancer Research Institute Testis Cancer Clinical Studies Group J Clin Oncol 25 2007 1310 1315 (Pubitemid 46706876)
55. P. Maroto, X. García del Muro, and J. Aparicio Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours Ann Oncol 16 2005 1915 1920 (Pubitemid 41724280)
56. T. Tandstad, G. Cohn-Cedermark, and O. Dahl Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study Ann Oncol 21 2010 1858 1863
57. A. Heidenreich, P. Albers, and M. Hartmann Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumours of the testis: experience of the German Testicular Cancer Study Group J Urol 169 2003 1710 1714 (Pubitemid 36443478)
58. J.P. Donohue, J.A. Thornhill, and R.S. Foster Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation J Urol 149 1993 237 243 (Pubitemid 23097564)
59. D.B. Lashley, and B.A. Lowe A rational approach to managing stage I nonseminomatous germ cell cancer Urol Clin North Am 25 1998 405 423 (Pubitemid 28384606)
60. P. Albers, R. Siener, and S. Kliesch Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumours: results of the German Testicular Cancer Study Group Trial J Clin Oncol 21 2003 1505 1512 (Pubitemid 46594103)
61. R.S. Foster, and B.J. Roth Clinical stage I nonseminoma: surgery versus surveillance Semin Oncol 25 1998 145 153 (Pubitemid 28201388)
62. C. Kratzik, W. Holtl, and W. Albrecht Risk adapted management for NSGCT stage I: long-term results of a multicenter study J Urol 155 1996 547A
63. J.P. Donohue, J.A. Thornhill, and R.S. Foster Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection Eur J Cancer 31A 1995 1599 1604
64. S.D. Williams, D.M. Stablein, and L.H. Einhorn Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer N Engl J Med 317 1987 1433 1438 (Pubitemid 17158165)
65. G. Janetschek, A. Hobisch, and R. Peschel Laparoscopic retroperitoneal lymph node dissection for clinical stage I non-seminomatous testicular carcinoma: long-term outcome J Urol 163 2000 1793 1796 (Pubitemid 30366738)
66. T. Tandstad, O. Dahl, and G. Cohn-Cedermark Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program J Clin Oncol 27 2009 2122 2128
67. G. Pizzocaro, N. Nicolai, and R. Salvioni Marker positive clinical stage I non seminomatous germ cell tumours (NSGCT) of the testis: which primary therapy? J Urol 155 Suppl 1996 328A
68. B.E. Davis, H.W. Herr, and W.R. Fair The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchidectomy J Urol 152 1994 111 113
69. P.W.M. Chung, M.K. Gospodarowicz, and T. Panzarella Stage II testicular seminoma: patterns of recurrence and outcome of treatment Eur Urol 45 2004 754 760 discussion 759-60 (Pubitemid 38638396)
70. X. Garcia-del-Muro, P. Maroto, and J. Gum Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study J Clin Oncol 26 2008 5416 5421
71. C.J. Logothetis, M.L. Samuels, and D.E. Selig Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report J Urol 134 1985 1127 1130 (Pubitemid 16207013)
72. J.P. Donohue, J.A. Thornhill, and R.S. Foster The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University Experience (1965 to 1989) J Urol 153 1995 85 89 (Pubitemid 24379804)
73. S.B. Saxman, D. Finch, and R. Gonin Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University Experience J Clin Oncol 16 1998 702 706 (Pubitemid 28135618)
74. R. De Wit, J.T. Roberts, and P.M. Wilkinson Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5- day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical research Council J Clin Oncol 19 2001 1629 1640 (Pubitemid 32230862)
75. S.D. Foss, S.B. Kaye, and G.M. Mead Filgrastim during combination chemotherapy of patients with poor prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom J Clin Oncol 16 1998 716 724
76. R.J. Motzer, C.J. Nichols, and K.A. Margolin Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors J Clin Oncol 25 2007 247 256 (Pubitemid 350003012)
77. C. Massard, A. Plantade, and M. Gross-Goupil Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases? Ann Oncol 21 2010 1585 1588
78. B.A. Murphy, R.J. Motzer, and M. Mazumdar Serum tumour marker decline is an early predictor of treatment outcome in germ cell tumour patients treated with cisplatin and ifosfamide salvage chemotherapy Cancer 73 1994 2520 2526 (Pubitemid 24155528)
79. F. André, K. Fizazi, and S. Culine The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients Eur J Cancer 36 2000 1389 1394 (Pubitemid 30421143)
80. S.D. Foss, S.P. Stenning, and A. Gerl Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 1999 1392 1399 (Pubitemid 29308608)
81. H.W. Herr, and G. Bosl Residual mass after chemotherapy for seminoma: changing concepts of management J Urol 137 1987 1234 1235 (Pubitemid 17079070)
82. H. Puc, R. Heelan, and M. Mazumdar Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center J Clin Oncol 14 1996 454 460 (Pubitemid 26051007)
83. C. Kollmannsberger, S. Daneshmand, and A. So Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery J Clin Oncol 28 2010 537 542
84. Y. Ehrlich, M.J. Brames, and S.D. Beck Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28 2010 531 536
85. H.W. Herr Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 80 1997 653 657 (Pubitemid 28316393)
86. E.W. Steyerberg, H.J. Kaiser, and J.D. Habbema Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group Int J Cancer 83 1999 856 859
87. A. Heidenreich, D. Pfister, and R. Witthuhn Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection Eur Urol 55 2009 217 226
88. K. Fizazi, J. Oldenburg, and A. Dunant Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study Ann Oncol 19 2008 259 264 (Pubitemid 351201705)
89. S.P. Stenning, M.C. Parkinson, and C. Fisher Postchemotherapy residual masses in germ cell tumor patients: content, clinical features and prognosis. Medical Research Council Testicular Tumour Working Party Cancer 83 1998 1409 1419
90. K.D. Miller, P.J. Loehrer, and R. Gonin Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma J Clin Oncol 15 1997 1427 1431 (Pubitemid 27167375)
91. H.J. Schmoll, and J. Beyer Prognostic factors in metastatic germ cell tumors Semin Oncol 25 1998 174 185 (Pubitemid 28201391)
92. International Prognostic Factors Study Group A. Lorch, and J. Beyer Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy J Clin Oncol 28 2010 4906 4911
93. R.J. Motzer, J. Sheinfeld, and M. Mazumdar Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer J Clin Oncol 18 2000 2413 2418 (Pubitemid 30415828)
94. A. Lorch, O. Rick, T. Wündisch, J.T. Hartmann, C. Bokemeyer, and J. Beyer High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors J Urol 184 2010 168 173
95. D.W. George, R.S. Foster, and R.A. Hromas Update on late relapse of germ cell tumor: a clinical and molecular analysis J Clin Oncol 21 2003 113 122
96. P. Albers, A. Ganz, and E. Hanning Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers J Urol 164 2000 381 384 (Pubitemid 30481930)
97. S.D. Foss, C. Bokemeyer, and A. Gerl Treatment outcome of patients with brain metastases from malignant germ cell tumors Cancer 85 1999 988 997 (Pubitemid 29077578)
98. J.T. Hartmann, M. Bamberg, and P. Albers Multidisciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumour (GCT) origin Proc Ann Soc Clin Oncol 22 2003 400 Abstract 1607